These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 16506358)
1. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease. Meier C; Meinhardt U; Greenfield JR; De Winter J; Nguyen TV; Dunstan CR; Seibel MJ Clin Lab; 2006; 52(1-2):1-10. PubMed ID: 16506358 [TBL] [Abstract][Full Text] [Related]
2. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Muñoz-Torres M; Reyes-García R; Mezquita-Raya P; Fernández-García D; Alonso G; Luna Jde D; Ruiz-Requena ME; Escobar-Jiménez F Maturitas; 2009 Nov; 64(3):188-92. PubMed ID: 19819089 [TBL] [Abstract][Full Text] [Related]
3. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177 [TBL] [Abstract][Full Text] [Related]
5. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094 [TBL] [Abstract][Full Text] [Related]
6. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women. Prezelj J; Ostanek B; Logar DB; Marc J; Hawa G; Kocjan T Menopause; 2008; 15(2):369-73. PubMed ID: 17882010 [TBL] [Abstract][Full Text] [Related]
7. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395 [TBL] [Abstract][Full Text] [Related]
8. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis. Shaarawy M; Zaki S; Sheiba M; El-Minawi AM Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333 [TBL] [Abstract][Full Text] [Related]
9. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Tumminello FM; Flandina C; Crescimanno M; Leto G Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092 [TBL] [Abstract][Full Text] [Related]
10. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335 [TBL] [Abstract][Full Text] [Related]
11. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401 [TBL] [Abstract][Full Text] [Related]
12. Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. Bonde M; Garnero P; Fledelius C; Qvist P; Delmas PD; Christiansen C J Bone Miner Res; 1997 Jul; 12(7):1028-34. PubMed ID: 9200001 [TBL] [Abstract][Full Text] [Related]
13. Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women. Kim BJ; Yu YM; Kim EN; Chung YE; Koh JM; Kim GS Clin Endocrinol (Oxf); 2007 Jul; 67(1):152-8. PubMed ID: 17466002 [TBL] [Abstract][Full Text] [Related]
14. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis. Verit FF; Geyikli I; Yazgan P; Celik A Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321 [TBL] [Abstract][Full Text] [Related]
15. Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. Garnero P; Gineyts E; Arbault P; Christiansen C; Delmas PD J Bone Miner Res; 1995 Apr; 10(4):641-9. PubMed ID: 7610936 [TBL] [Abstract][Full Text] [Related]
16. Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women. Adolf D; Wex T; Jahn O; Riebau C; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S; Piatek S Maturitas; 2012 Feb; 71(2):169-72. PubMed ID: 22197348 [TBL] [Abstract][Full Text] [Related]
17. Paget's disease of bone: experience from a centre in southern India. Anjali ; Thomas N; Rajaratnam S; Shanthly N; Oommen R; Seshadri MS J Assoc Physicians India; 2006 Jul; 54():525-9. PubMed ID: 17089899 [TBL] [Abstract][Full Text] [Related]
18. Serum bone specific alkaline phosphatase and urinary deoxypyridinoline in postmenopausal osteoporosis. Nawawi HM; Yazid TN; Ismail NM; Mohamad AR; Nirwana SI; Khalid BA Malays J Pathol; 2001 Dec; 23(2):79-88. PubMed ID: 12166596 [TBL] [Abstract][Full Text] [Related]